What question did this study set out to answer?

To determine whether anti-ADAMTS13 antibody titers and their trajectory during the acute phase predict ADAMTS13 activity recovery in immune-mediated thrombotic thrombocytopenic purpura.

July 15, 2025American Journal of HematologyOpen Access

Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP

View Full Paper

Ask AI

Bookmark

Authors

MRMarie RobertUniversité Claude Bernard Lyon 1 AMArthur MageauDélégation Paris 5 YBY. BenhamouHôpital Charles-Nicolle

Discussion

Member takes

Implication

Cohort study reveals that early anti-ADAMTS13 antibody decline predicts enzyme recovery in immune-mediated TTP, suggesting antibody tracking can guide timely immunosuppression intensification.

Key Points

To determine whether anti-ADAMTS13 antibody titers and their trajectory during the acute phase predict ADAMTS13 activity recovery in immune-mediated thrombotic thrombocytopenic purpura.
Evaluated anti-ADAMTS13 IgG antibody titers in a discovery cohort of 286 patients receiving a triplet regimen of therapeutic plasma exchange, corticosteroids with rituximab, and caplacizumab.
Assessed antibody titer changes between days 7 and 14 post-plasma exchange to predict ADAMTS13 recovery (activity ≥ 20% before day 30), validating findings in an independent cohort (N = 51).
A baseline anti-ADAMTS13 IgG cutoff of 90.5 U/mL demonstrated modest predictive value for recovery (AUC: 0.57), limiting its utility for guiding treatment.
Patients exhibiting a decrease in antibody titers within 7–14 days post-plasma exchange achieved significantly higher rates of ADAMTS13 recovery than non-decreasers (65% vs. 25%, p < 0.001), a pattern verified in the validation cohort (N = 51).

Cite This Study

Robert et al. (2025) studied this question.

synapsesocial.com/papers/6a9fe7f025a538586e5cc30f https://doi.org/10.1002/ajh.70005

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals that early anti-ADAMTS13 antibody decline predicts enzyme recovery in immune-mediated TTP, suggesting antibody tracking can guide timely immunosuppression intensification.

Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP

Discussion

Member takes

Implication

Key Points

Cite This Study

Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider